List of Exem Foam Kit drug patents

Exem Foam Kit is owned by Giskit.

Exem Foam Kit contains Air Polymer-Type A.

Exem Foam Kit has a total of 3 drug patents out of which 0 drug patents have expired.

Exem Foam Kit was authorised for market use on 07 November, 2019.

Exem Foam Kit is available in foam;intrauterine dosage forms.

Exem Foam Kit can be used as use in sonohysterosalpinography to assess fallopian tube patency.

Drug patent challenges can be filed against Exem Foam Kit from November, 2023.

The generics of Exem Foam Kit are possible to be released after 11 February, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(7 years from now)

US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(12 years from now)

US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in